

-Translation-

NAM 2026/057

14 May 2026

**Subject:** Establishment of a subsidiary

**To:** President

The Stock Exchange of Thailand

Pursuant to that the Board of Directors' meeting of Namwiwat Medical Corporation Public Company Limited (the "Company") held on May 13, 2025, have resolved to approve the establishment of a new subsidiary in Italy. The Company has not yet been able to disclose such resolution of the Board of Directors to the SET promptly due to the entering into such investment transactions is still uncertain and the Company is required to maintain information related to such transactions in confidential during the course of negotiations of relevant contracts and conditions, however, the Board of Directors' meeting have assigned the Chief Executive Officer to immediately disclose the detailed information to the SET upon all conditions and terms of the transaction have been mutually agreed. The Company therefore wishes to inform details of the establishment of the new subsidiary in Italy as follows:

**Established Company's Name** : Sterion Italia S.r.l.

**Registered under the laws** : Italy

**Registration Date** : April 27, 2026

**Type of business** : To manufacture and/or distribute and/or market cleaning and sterilization systems for healthcare facilities, pharmaceutical and research laboratories, surgical instruments and equipment, indicators, and research-related products, whether directly or on behalf of the sponsor's affiliated companies, both within Italy and internationally (within and outside the European Union).

**Investment Objectives** :

1. To establish collaboration in research and development (R&D).
2. To expand the customer base and enhance the Company's brand awareness.
3. To increase business opportunities and distribution channels for the Company's products.

Registered Capital : 20,000,000 Baht (Initial registered capital of 4,736,750 baht. or EUR 125,000)

Shareholding Structure : Namwiwat Medical Corporation Public Company Limited holds 100% of shares in the newly established company.

Director Structure : Mr. Viroj Chaiturdkiet

Source of Fund : The Company's working capital.

This transaction is not classified as a connected transaction as defined under the notification of the Capital Market Supervisory Board No. TorJor. 21/2551 Re: Rules on Connected Transactions dated August 31, 2008 (as amended) and the Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Companies Concerning the Connected Transactions dated November 19, 2003 (as amended). Upon consolidating the investment value at this time and after combining this with the acquisition of the other assets of the Company during the six months prior to the transaction, it was determined that the transaction size is less than 15 percent. Consequently, this transaction does not require the disclosure of information under the Notification of the Capital Market Supervisory Board No. TorJor. 20/2551 Re: Rules on Entering into Material Transactions Deemed as Acquisition or Disposal of Assets dated August 31, 2008 (as amended) and the Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Companies Concerning the Acquisition and Disposition of Assets, 2004 dated October 29, 2004 (as amended).

However, the Company has a duty to report information that a listed company or its subsidiary company acquires investment in other company, which results in such company becoming the subsidiary of the Company.

Please be informed accordingly.

Yours Sincerely,

*-Mr.Viroj Chaiturdkiet-*

(Mr.Viroj Chaiturdkiet)

Chief Executive Officer

Namwiwat Medical Corporation Public Company Limited